Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Worksport Q4 FY2025 Earnings Call - Net Sales Nearly Doubled to $16.1M, Margins Jump to ~28%, Cash-Flow Target H2 2026
Worksport reported a sharp operational inflection in fiscal 2025, with net sales up 89.8% to $16.1 million and gross margins expanding roughly 2,800 basis points to about 28% for the year, rising to r...
- Net sales nearly doubled year over year to $16.1 million in fiscal 2025, up 89.8% from $8.5 million in 2024.
- Gross margin expanded dramatically from about 11% in 2024 to 28% for fiscal 2025, with Q4 margin near 30%.
- Management attributes margin expansion to higher capacity utilization at the New York factory and a shift to higher-margin hardcover products.
- +12 more takeaways
Laird Superfood Q4 2025 Earnings Call - Navitas Acquisition and Nexus $50M Investment Turn Laird Into a Scaled Superfood Platform
Laird Superfood closed 2025 with record net sales of $49.9 million, up 15% year over year, and a strong wholesale acceleration that lifted Q4 sales to $13.3 million. Management credited distribution g...
- Record 2025 net sales of $49.9 million, up 15% year over year; Q4 net sales were $13.3 million, also up 15% versus prior year.
- Wholesale was the growth engine, rising 44% in Q4 and 41% for the full year, and now represents roughly half of total sales.
- E-commerce remains about half of sales, but platform mix shifted: Amazon grew while direct-to-consumer declined, with DTC down 6% in Q4 and e-commerce down 3% for the year.
- +11 more takeaways
Insight Molecular Diagnostics Q4 2025 Earnings Call - FDA submission of GraftAssureDx shifts company into commercialization ramp
Insight Molecular Diagnostics centered this quarter on a clear inflection, the FDA submission of GraftAssureDx, which the company says is the first dd-cfDNA assay submitted for authorization. Manageme...
- Company submitted GraftAssureDx to the FDA for review, positioning the business to move from development into commercialization.
- Management claims, to their knowledge, GraftAssureDx is the first dd-cfDNA assay submitted to the FDA for authorization, a potential first-mover messaging point.
- Launch plan rests on three activation levers, registry engagement, head-to-head comparative data, and early adopters running the RUO version in-house.
- +15 more takeaways
Argan, Inc. Q4 & FY2026 Earnings Call - Record results and $2.9B backlog signal accelerating demand for gas-fired projects
Argan closed fiscal 2026 with a clean, punchy set of numbers: record revenue and profit, a ballooning backlog, and a fortress-like balance sheet. Q4 revenue hit $262.1 million and the full year reache...
- Record Q4 revenue of $262.1 million and record FY2026 revenue of $944.6 million, driven primarily by the Power segment.
- Q4 gross profit of $65.6 million, Q4 gross margin 25%, and fiscal 2026 gross margin 20.5%, up from 16.1% in FY2025.
- Record Q4 net income of $49.2 million, or $3.47 per diluted share, and FY2026 net income of $137.8 million, or $9.74 per diluted share.
- +13 more takeaways
Oxford Industries, Inc. Fourth Quarter Fiscal 2025 Earnings Call - Tariff Hit and Lyons Ramp Mask Early Signs of Brand Recovery
Oxford closed fiscal 2025 with clear fault lines. A sharp tariff shock and ramp costs from a new Lyons, Georgia distribution center knocked adjusted EBITDA and EPS well below prior-year levels, even a...
- Tariffs are the headline blow: Oxford expects total IEEPA-related tariff headwinds of $50 million in fiscal 2026, including an incremental $20 million versus FY2025, representing roughly 150 basis points of gross margin and about $1.00 of EPS impact for the year.
- Heavy Q1 tariff pain baked in: The company expects approximately $12 million of incremental tariff costs in Q1 FY2026, equal to roughly a 300 basis point gross margin headwind and about $0.60 per share of EPS pressure versus last year.
- Adjusted EBITDA collapsed year over year: FY2025 adjusted EBITDA fell to $107 million, a 7.2% margin, down from $193 million and a 12.7% margin in FY2024.
- +12 more takeaways
Veritone, Inc. Q4 2025 Earnings Call - Oracle Deal and a Binary $12.9M Data Rights Transaction That Could Unlock $100M VDR Revenue
Veritone reported preliminary Q4 2025 results with a wide revenue range driven almost entirely by one complex, non-cash transaction: an on-prem sale of aiWARE software with $12.9 million face value in...
- Preliminary Q4 revenue range is $18.1 million to $30.0 million, driven almost entirely by one multi-party, non-monetary transaction with a $12.9 million stated software price.
- The $12.9 million transaction exchanged on-prem aiWARE software for intangible data rights and preferred customer access, including potential access to more than 50 million hours of monetizable datasets.
- GAAP accounting for the transaction is uncertain, because the value realization is prospective; the standalone selling price may be substantially discounted, making reported revenue binary and timing dependent.
- +11 more takeaways
Xos, Inc. Q4 and Full Year 2025 Earnings Call - Positive Free Cash Flow and Shift to Hubs and Powertrains
Xos says 2025 was a pivot year: the company turned a $49.1 million free cash flow hole in 2024 into $5.4 million of positive free cash flow in 2025, narrowed operating losses, and delivered more units...
- Xos reported full year 2025 revenue of $46.0 million on 328 units, the most units in company history.
- The company generated $5.4 million of positive free cash flow in 2025, a $54 million swing from negative $49.1 million in 2024.
- GAAP gross margin for 2025 was 5.9% ($2.7 million), marking the second consecutive full year of positive GAAP and non-GAAP gross margins.
- +16 more takeaways
IRIDEX Q4 2025 Earnings Call - Turnaround Delivers Positive Adjusted EBITDA and Q4 Cash Flow, Margin Fix Is Work in Progress
IRIDEX closed 2025 with a clear glidepath to profitability: full-year revenue of $52.7 million (up 8% YoY), positive adjusted EBITDA for the first time in recent history, and positive operating cash f...
- Full-year 2025 revenue was $52.7 million, up 8% year-over-year versus 2024.
- IRIDEX achieved positive adjusted EBITDA for full-year 2025 and generated positive operating cash flow in Q4 2025.
- Q4 2025 revenue was $14.7 million, a 16% year-over-year increase driven by higher retina and glaucoma probe sales.
- +15 more takeaways
Blink Charging Co. Q4 2025 Earnings Call - Restructured to Cut Burn to $2M/Quarter and Shift to Recurring Service Revenue
Blink’s Q4 and full year 2025 call was a report card on survival and reset. The Blink Forward program materially reshaped the company, halving headcount, exiting in-house manufacturing, taking a one-t...
- Blink Forward delivered a material reset, the company says it substantially met its 2025 objectives and repositioned Blink as a leaner, financially focused business.
- Headcount was cut from roughly 600 employees at the start of 2025 to fewer than 300 today, part of a drive to right-size the cost base.
- Blink completed its shift to contract manufacturing, exiting in-house production to reduce working capital intensity and supply chain complexity.
- +15 more takeaways
Daré Bioscience FY2025 Earnings Call - DARE to PLAY pre-fulfillment live nationwide, revenue expected Q2 2026
Daré presented a clear, execution-focused year end 2025 update, pivoting from R&D heavy years into commercial activation. The headline is DARE to PLAY, a GMP-made topical sildenafil cream backed by pu...
- DARE to PLAY, a topical sildenafil cream with published clinical data showing increased genital blood flow within 10-15 minutes, went live for pre-fulfillment prescriptions in all 50 states as of February 11, 2026.
- Telehealth access for DARE to PLAY launched alongside pre-fulfillment, enabling remote prescribing; dispensing will begin once the 503B outsourcing facility completes state licensing and fulfillment preparations.
- Daré is using a dual path commercial strategy: immediate 503B compounding to generate prescriptions and real-world data, while simultaneously pursuing a 505(b)(2) NDA for the sildenafil cream.
- +12 more takeaways